Cornea neovascularisation treatment

An expert panel of ophthalmologists have published a consensus statement online in the British Journal of Ophthalmology on the management of neovascularisation associated with corneal diseases. The panel call for a framework to manage the disorder more efficiently, including the use of antiangiogenic drugs. 'There is a significant unmet need in the treatment of corneal neovascularisation. We believe that this could be met by using novel antiangiogenic therapies, which will eventually become an integral part of our treatment strategy,' explained Dr Claus Cursiefen, chairman and professor Department of Ophthalmology, University of Cologne, Germany, a panel participant and lead author for the consensus statement while at Friedrich-Alexander University Erlangen-Nürnberg. 'The panel believes that a framework for clinical evaluation and agreement on clinically relevant end points will assist future drug development and support regulatory authorities during their review of clinical trial data. This consensus statement provides an initial step in proposing this new framework.'